Ankyra Therapeutics
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
Ankyra Therapeutics is a clinical-stage company developing a new class of drug conjugates that not only deliver, but anchor therapeutic molecules at the tumor site, maximizing antitumor activity while minimizing systemic toxicity. Our Anchor-Drug Conjugate (ADC) platform leverages a proprietary alum-binding peptide to conjugate therapeutic payloads, such as cytokines and antibodies, to aluminum hydroxide. This anchoring enables a multi-fold increase in intratumoral drug concentration compared to conventional delivery approaches, extending drug exposure at the tumor site and expanding the therapeutic window. Our lead program, an IL-12 Anchor-Drug Conjugate, has demonstrated encouraging biological activity and safety in Phase 1, including objective responses in a monotherapy setting. We are actively building a diversified pipeline of anchored immunotherapies, focused on rescuing clinically validated but previously undeliverable payloads due to safety concerns.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}